Stockholders of Exact Sciences have approved the company’s proposed acquisition by Abbott, with more than 99% of votes cast in favor of the transaction. Pending final regulatory approvals and other closing conditions, the deal is expected to be completed by the end of the second quarter of 2026. Upon completion, Exact Sciences shareholders will receive $105 in cash per share. The acquisition brings Abbott into Exact Sciences’ portfolio of cancer diagnostics and screening solutions, including stool-based colorectal cancer screening and multi-cancer early detection technologies currently available in the United States.
Author: Abhay Panchal
Advances in ingestible electronics are paving the way for next-generation “smart pills” that can both diagnose and treat gastrointestinal diseases from within the body. These capsule-sized devices integrate miniaturized sensors, actuators, and wireless communication systems to monitor biomarkers, assess tissue health, and transmit real-time data as they travel through the GI tract. Beyond diagnostics, emerging prototypes are being designed to deliver drugs directly to diseased tissue or collect biopsy samples using low-power mechanical systems—potentially reducing the need for invasive procedures such as endoscopy. Ongoing research is focused on overcoming key challenges related to power supply, biocompatibility, and miniaturization, with the…
In the latest edition of The Scope Forward Show, I’m joined by: Matt Schwartz, Founder & CEO of VirgoDr. Neil Parikh, Chief Innovation Officer, Connecticut GI and Chair of Innovation, GI Alliance This isn’t an interview. It’s a raw, unscripted exploration of where AI in GI is actually headed—guided by the latest headlines and hard questions. Here’s what we unpack: We also dive into: This isn’t about polyp detection anymore. It’s about: If you think AI in GI is limited to ambient listening and green bounding boxes… This conversation will challenge you. If you sense something much bigger unfolding… You shouldn’t miss this one.…
As demand grows for alternatives to costly GLP-1 therapies, AI-powered “digital twins” are emerging as a novel approach to managing chronic metabolic conditions such as diabetes and obesity. Startups like Twin Health are combining wearable sensor data with machine learning to create individualized metabolic models that guide real-time lifestyle interventions. By continuously analyzing biomarkers and behavioral inputs, these virtual replicas aim to support sustained weight loss and glycemic control without pharmacologic therapy. Early patient experiences suggest that personalized, data-driven recommendations may help overcome the limitations of traditional diet-based approaches, offering a scalable, non-drug pathway for long-term chronic disease management.
The U.S. healthcare system is approaching a tipping point, driven by three converging threats: rising care costs, a growing chronic disease burden, and a physician workforce trained for a rapidly outdated model of care. With national healthcare spending projected to surpass $7 trillion by the end of the decade, incremental policy fixes are unlikely to keep pace with mounting financial and clinical pressures. As chronic conditions like diabetes continue to drive long-term complications and high-cost care, prevention alone may not be sufficient to offset system-wide strain. In response, generative AI is emerging as a potential force multiplier—automating routine monitoring and…
New research presented at the 2026 Crohn’s & Colitis Congress® highlights a rapidly evolving therapeutic landscape in inflammatory bowel disease (IBD), spanning metabolic drugs, engineered microbiome therapies, and real-world treatment data. GLP-1 receptor agonists—commonly used for obesity and diabetes—were associated with improved IBD outcomes across independent cohorts, including reduced corticosteroid use, fewer hospitalizations, intestinal surgeries, and lower mortality, without increased surgical risk. These findings suggest potential benefits beyond metabolic disease and warrant further prospective evaluation in IBD populations. Researchers also introduced a next-generation live biotherapeutic for ulcerative colitis: a genetically engineered strain of E. coli Nissle 1917 designed to selectively…
Independent physician practices are facing mounting financial strain as operating costs rise faster than reimbursements, driving many toward consolidation with hospitals, insurers, or private equity firms. Lingering pandemic-related revenue drops, combined with increasing expenses tied to staffing, compliance, technology, and malpractice coverage, are further tightening cash flow across midsize practices. These pressures are reshaping how practices approach growth and financing. Traditional lenders are placing greater emphasis on predictable cash flow, EBITDA margins, accounts receivable timelines, and payer mix—factors that can significantly influence access to capital. In this environment, practices with inconsistent revenue cycles or heavy dependence on government payers may…
For years, gut health has been used liberally across research papers, probiotic marketing campaigns, and patient conversations—often without a consistent clinical definition. Now, a new 2026 consensus statement from the International Scientific Association for Probiotics and Prebiotics (ISAPP), published in Nature Reviews Gastroenterology & Hepatology, attempts to bring much-needed clarity to a term that sits at the intersection of microbiome science, GI physiology, and patient-reported outcomes. For gastroenterologists, the key shift is this: gut health is no longer defined solely by the absence of disease—but by the presence of normal GI function and the absence of symptoms that meaningfully impact…
Medical malpractice continues to be an occupational reality in gastroenterology. In fact, a landmark study by Jena et al. found that most gastroenterologists will face at least one lawsuit over the course of their careers. While many claims never result in financial penalties, the emotional toll, reputational risk, and time burden can be substantial. In GI practice, litigation is most often triggered by missed or delayed diagnoses, endoscopic complications—particularly during ERCP—perforations, and breakdowns in communication. And in today’s fast-paced clinical environment, opportunities to build rapport with patients are becoming increasingly limited. Workflows like open-access endoscopy and reliance on electronic medical…
Artificial intelligence is steadily moving from hype to hands-on utility in endoscopy suites. In this edition of Sharma’s Endoscopy Insights, two recent studies explore how AI could enhance both optical diagnosis and quality measurement during colonoscopy. The first study evaluated computer-aided diagnosis (CADx) in identifying sessile serrated lesions (SSLs)—a known blind spot in colorectal cancer prevention. Endoscopists demonstrated higher diagnostic accuracy when CADx supported optical classification, particularly in distinguishing SSLs from hyperplastic polyps. However, current systems still face limitations in reliably characterizing these lesions, highlighting the need for further refinement. The second study focused on withdrawal time, a key colonoscopy…